La cara oculta de la investigación.

  1. Franco-López, Ángeles
  2. Jáuregui-Lobera, Ignacio
  3. Culebras, Jesús M.
Aldizkaria:
Journal of Negative and No Positive Results: JONNPR

ISSN: 2529-850X

Argitalpen urtea: 2017

Alea: 2

Zenbakia: 6

Orrialdeak: 222-225

Mota: Artikulua

DOI: 10.19230/JONNPR.1478 DIALNET GOOGLE SCHOLAR lock_openSarbide irekia editor

Beste argitalpen batzuk: Journal of Negative and No Positive Results: JONNPR

Garapen Iraunkorreko Helburuak

Laburpena

En EEUU la ley exige que se publiquen los resultados de todos los ensayos clínicos en un plazo máximo de doce meses. La realidad es que aproximadamente el 50% de los ensayos clínicos quedan sin publicar. Esto constituye un grave problema porque no se puede progresar de manera óptima en el descubrimiento y desarrollo de nuevas terapias si no hay transparencia en los ensayos clínicos. Powell Smith y Goldcare han puesto a punto una herramienta informática, The Trials Tracker (El controlador de ensayos), que identifica automáticamente los ensayos clínicos acabados de los promotores, detecta los que no son publicados y hace estadística sobre la incidencia. Esta herramienta permite desenmascarar a los que con mayor frecuencia ocultan resultados negativos. 

Erreferentzia bibliografikoak

  • Anna Powell-Smith, Ben Goldacre. The TrialsTracker: Automated ongoing monitoring of failure to share clinical trial results by all major companies and research institutions [version 1; referees: 2 approved]. F1000Research 2016, 5:2629 Last updated: 06 JAN 2017
  • Barbui C, Furukawa TA, Cipriani A. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ 2008;178(3):296-305
  • Culebras JM. Dos malas noticias. JONNPR. 2016;1(4):123-124 123 DOI: 10.19230/jonnpr.2016.1.4.1017
  • Joanna Le Noury, John M Nardo, David Healy, Jon Jureidini, Melissa Raven, Catalin Tufanaru, Elia Abi-Jaoude. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence BMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h4320 (Published 16 September 2015)
  • Joe Biden: Agencies don’t report clinical trials should lose funds. STAT. 2016. https://www.reddit.com/r/Health/comments/4qhqi9/joe_biden_agencies_dont_report_clinical_trials/
  • Patients endangered as law is ignored. STAT. 2015.
  • Schmucker C, Schell LK, Portalupi S, et al.: Extent of Non-Publication in Cohorts of Studies Approved by Research Ethics Committees or Included in Trial Registries. PLoS One. 2014; 9(12): e114023.
  • Slade E., H. Drysdale, B. Goldacre. "Discrepancies Between Prespecified and Reported Outcomes." BMJ 11 November 2015. http://www.bmj.com/content/351/bmj.h5627/rr-12
  • SmithKline Beecham. A multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression –acute phase, Final clinical report. www.gsk.com/media/389566/depression_329_full.pdf.
  • Song F, Parekh S, Hooper L, et al.: Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess. 2010; 14(8): iii,ix–xi, 1–193.
  • Weston, J., K. Dwan, D. Altman, M. Clarke, C. Gamble, S. Schroter, P. Williamson, and J. Kirkham. “Feasibility study to examine discrepancy rates in prespecified and reported outcomes in articles submitted to The BMJ.” BMJ Open 2016;6:4 e010075 doi:10.1136/bmjopen-2015-010075; http://bmjopen.bmj.com/content/6/4/e010075